ADMA - CIK 0001368514
The table below shows ADMA BIOLOGICS, INC.'s cash flow statement line items across its last 6 fiscal years, exactly as reported in the company's audited annual filings. All figures are in US dollars; negative values appear in red.
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Operating cash flow | $50.40M | $118.67M | $8.80M | -$59.51M | -$112.37M | -$102.00M |
| Capital expenditure | $22.57M | $8.23M | $4.77M | $13.91M | $13.51M | $12.73M |
| Investing cash flow | -$21.89M | -$8.57M | -$4.98M | -$13.91M | -$13.51M | -$12.72M |
| Dividends paid | - | - | - | - | - |
ADMA BIOLOGICS, INC. reported operating cash flow of $50.40M for fiscal year 2025. That is down 57.5% from $118.67M in fiscal 2024. Over the 10 fiscal years shown, operating cash flow grew from -$18.27M (FY 2016) to $50.40M. Figures come from the company's audited annual reports as filed with the SEC.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| - |
| Stock buybacks | $31.94M | $0.00 | $0.00 | - | - | - |
| Financing cash flow | -$44.02M | -$58.30M | -$38.99M | $108.85M | $121.05M | $143.90M |